JW Vardiman

4.0k total citations · 1 hit paper
52 papers, 3.3k citations indexed

About

JW Vardiman is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, JW Vardiman has authored 52 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 24 papers in Genetics and 16 papers in Public Health, Environmental and Occupational Health. Recurrent topics in JW Vardiman's work include Acute Myeloid Leukemia Research (26 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Acute Lymphoblastic Leukemia research (15 papers). JW Vardiman is often cited by papers focused on Acute Myeloid Leukemia Research (26 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Acute Lymphoblastic Leukemia research (15 papers). JW Vardiman collaborates with scholars based in United States. JW Vardiman's co-authors include JD Rowley, HM Golomb, Richard A. Larson, MM Le Beau, MJ Ratain, JR Testa, Jacobs Rh, John Anastasi, CM Rubin and Maya Thangavelu and has published in prestigious journals such as Blood, PubMed and Medical Entomology and Zoology.

In The Last Decade

JW Vardiman

52 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease

1981 384 citations JD Rowley, HM Golomb et al. Blood profile →

Peers

Countries citing papers authored by JW Vardiman

Since Specialization

Citations

This map shows the geographic impact of JW Vardiman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JW Vardiman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JW Vardiman more than expected).

Fields of papers citing papers by JW Vardiman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JW Vardiman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JW Vardiman. The network helps show where JW Vardiman may publish in the future.

Co-authorship network of co-authors of JW Vardiman

This figure shows the co-authorship network connecting the top 25 collaborators of JW Vardiman. A scholar is included among the top collaborators of JW Vardiman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JW Vardiman. JW Vardiman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SPOTLIGHT REVIEW Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms 2008 ·Ayalew Tefferi, JW Vardiman	4
2	Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders 1992 ·Blood ·(unknown), CM Rubin, (unknown), Richard A. Larson, MM Le Beau, JD Rowley, JW Vardiman, (unknown), (unknown)	45
3	Clinical and cytogenetic responses to granulocyte-macrophage colony- stimulating factor in therapy-related myelodysplasia 1992 ·Blood ·WJ Gradishar, MM Le Beau, (unknown), JW Vardiman, Richard A. Larson	21
4	CD5+, CD11c+, CD20+ hairy cell leukemia [letter; comment] 1991 ·Blood ·(unknown), JW Vardiman, Wendy Stock, (unknown), HM Golomb	10
5	Interphase cytogenetic analysis detects minimal residual disease in a case of acute lymphoblastic leukemia and resolves the question of origin of relapse after allogeneic bone marrow transplantation 1991 ·Blood ·John Anastasi, Maya Thangavelu, JW Vardiman, (unknown), (unknown), Richard A. Larson, MM Le Beau	50
6	Trisomy 6: a recurring cytogenetic abnormality associated with marrow hypoplasia [letter] 1991 ·Blood ·(unknown), CM Rubin, MM Le Beau, JW Vardiman, Richard A. Larson, JN Winter	27
7	Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia [see comments] 1990 ·Blood ·(unknown), Rosemarie Mick, (unknown), (unknown), MJ Ratain, JW Vardiman, HM Golomb	43
8	Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia [see comments] 1990 ·Blood ·(unknown), Rosemarie Mick, (unknown), (unknown), MJ Ratain, JW Vardiman, HM Golomb	1
9	Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. 1988 ·PubMed ·(unknown), Richard A. Larson, Le Beau, (unknown), (unknown), JW Vardiman, (unknown), (unknown), (unknown)	60
10	Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes 1986 ·Blood ·Jacobs Rh, (unknown), JW Vardiman, Richard A. Larson, MM Le Beau, JD Rowley	211
11	Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis 1986 ·Blood ·Richard A. Larson, SF Williams, MM Le Beau, MA Bitter, JW Vardiman, JD Rowley	8
12	Sequential treatment of hairy cell leukemia: a new role for interferon. 1986 ·PubMed ·HM Golomb, (unknown), JW Vardiman	12
13	Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes 1986 ·Blood ·Jacobs Rh, (unknown), JW Vardiman, Richard A. Larson, MM Le Beau, JD Rowley	9
14	Treatment of hairy cell leukemia with recombinant alpha 2 interferon 1985 ·Blood ·MJ Ratain, HM Golomb, JW Vardiman, E. Vokes, Jacobs Rh, Karen Daly	129
15	Chlorambucil therapy of twenty-four postsplenectomy patients with progressive hairy cell leukemia. 1984 ·PubMed ·HM Golomb, (unknown), JW Vardiman	21
16	Autopsy findings in hairy cell leukemia. 1984 ·PubMed ·JW Vardiman, (unknown)	38
17	Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia 1982 ·Blood ·HM Golomb, (unknown), JD Rowley, JW Vardiman, JR Testa, (unknown)	127
18	Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease 1981 ·Blood ·JD Rowley, HM Golomb, JW Vardiman	24
19	Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease breakdown → 1981 ·Blood ·JD Rowley, HM Golomb, JW Vardiman	384
20	Hypergranular promyelocytic leukemia (APL): cytogenetic and ultrastructural specificity 1978 ·Blood ·JR Testa, H M Golomb, JD Rowley, JW Vardiman, (unknown)	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact